Pascal Biosciences Inc (NEVI) AI Stock Analysis

• Market Cap: C$2.18M
• Dividend Yield: N/A
• Average Volume (3M): 103.84K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.46
• Revenue Growth: 5.31%
• EPS Growth: 41.57%
• Country: CA
• Employees: 2
• Sector: Consumer Defensive
• Sector Strength: 53
• Industry: Beverages - Non-Alcoholic
• EPS (TTM): 0.00
• Shares Outstanding: 39,662,727
• 10 Day Avg. Volume: 49,760
• 30 Day Avg. Volume: 103,842
• PEG Ratio: 0.25
• Price to Book (P/B): 3.28
• Price to Sales (P/S): 2.60
• P/FCF Ratio: -30.47
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Hold
• Number of Analyst Covering: 0

• Rating: 51 Neutral
• Price Target: C$0.00 ▼(-100.00% Downside)

The stock score reflects moderate financial performance and technical analysis indicators, balanced by positive corporate events. While financial challenges persist, strategic expansions and market penetration efforts present potential growth opportunities.

Pascal Biosciences Inc Business Overview & Revenue Model

Company Description

Pascal Biosciences Inc (NEVI) is a biotechnology company focused on the discovery and development of innovative therapies for the treatment of cancer and other serious diseases. The company operates primarily in the pharmaceutical sector, leveraging its proprietary technology and expertise to create novel drug candidates. Pascal Biosciences is dedicated to advancing its pipeline through research and collaboration, aiming to bring effective solutions to patients in need.

How the Company Makes Money

Pascal Biosciences Inc generates revenue primarily through the development and commercialization of its drug candidates. The company seeks to monetize its proprietary technologies and compounds through partnerships and licensing agreements with larger pharmaceutical firms. These collaborations often involve milestone payments, research funding, and royalties on sales of successfully developed products. Additionally, Pascal may receive grants and funding from governmental and non-governmental organizations to support its research and development efforts. The company's revenue model is heavily reliant on successful drug development and strategic partnerships within the biotech and pharmaceutical industry.

Pascal Biosciences Inc Financial Statement Overview

Summary

Pascal Biosciences Inc shows moderate revenue growth and positive operational cash flow. However, ongoing profitability challenges and historical negative equity pose significant financial risks.

Income Statement

Pascal Biosciences Inc has shown a moderate improvement in revenue with a TTM revenue of $1,585,656, representing growth from previous periods. However, the company is still facing challenges in profitability with a negative net income of -$259,009. The gross profit margin stands at 61.8%, which is healthy, but the net profit margin is negative due to high operational expenses relative to revenue. EBITDA has turned positive in the TTM, indicating some operational improvement.

Balance Sheet

The balance sheet shows a relatively stable position with total assets of $2,069,189 and stockholders' equity of $1,291,036. The debt-to-equity ratio is 0.36, indicating a reasonable level of leverage. Equity ratio at 62.4% reflects a solid capital structure. However, the company has a history of negative equity, which poses potential financial risks.

Cash Flow

Cash flow from operations is marginally positive at $14,507, signaling a slight recovery. Free cash flow is also positive at $26,962 in the TTM, showing improvement from previous years. However, the free cash flow to net income ratio is negative due to ongoing net losses, and reliance on financing is evident with a significant negative financing cash flow.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	1.57M	1.55M	671.54K	0.00	0.00	0.00
Gross Profit	1.18M	1.08M	392.94K	-8.29K	-16.32K	-12.48K
EBITDA	103.62K	-48.07K	-266.92K	-468.09K	-1.07M	-1.22M
Net Income	-205.76K	-362.48K	-399.77K	-480.28K	-1.09M	-1.24M
Balance Sheet
Total Assets	1.94M	2.04M	2.50M	18.82K	155.19K	120.71K
Cash, Cash Equivalents and Short-Term Investments	53.63K	129.54K	418.52K	8.37K	0.00	0.00
Total Debt	459.74K	528.30K	683.27K	224.62K	7.76K	16.91K
Total Liabilities	733.93K	813.50K	1.12M	962.93K	646.48K	473.05K
Stockholders Equity	1.21M	1.23M	1.38M	-944.11K	-491.30K	-352.34K
Cash Flow
Free Cash Flow	9.55K	-132.06K	-390.49K	-147.68K	-614.93K	-862.83K
Operating Cash Flow	9.55K	-120.50K	-385.35K	-147.68K	-614.93K	-862.83K
Investing Cash Flow	87.56K	-11.56K	-947.71K	8.98K	0.00	0.00
Financing Cash Flow	-143.29K	-167.65K	1.76M	154.84K	624.08K	471.07K

Pascal Biosciences Inc Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 0.06
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:NEVI, the sentiment is Neutral. The current price of 0.06 is below the 20-day moving average (MA) of 0.06, below the 50-day MA of 0.06, and below the 200-day MA of 0.07, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 48.15 is Neutral, neither overbought nor oversold. The STOCH value of 66.67 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for TSE:NEVI.

Pascal Biosciences Inc Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	63 Neutral	$20.84B	14.73	-4.08%	3.07%	2.70%	-8.60%
NEVI	51 Neutral	C$2.18M	―	-16.65%	―	5.31%	41.57%
RAMM	40 Underperform	C$1.19M	―	-70.13%	―	-10.69%	-53.89%

Pascal Biosciences Inc Corporate Events

Nevis Brands Expands Midwest Reach with Strategic Distribution Agreement

Nevis Brands Inc. has announced a strategic distribution agreement with Z.T. Distribution Inc. to expand the reach of its hemp-derived THC beverage, Happy Apple™, in Wisconsin, Minnesota, and Illinois. This partnership with ZT, a well-established distributor, is expected to enhance Nevis Brands’ market penetration and capitalize on the growing demand for hemp-derived beverages, aligning with the company’s strategy to broaden its footprint in the U.S. market.

Nevis Brands Sees Revenue Growth Amid New Product Launches

Nevis Brands Inc. reported a slight increase in revenue for Q2 2025, driven by stable performance in its licensed markets and the introduction of its hemp-derived THC product line. Despite stable gross margins, the company faced a net loss due to foreign exchange pressures and elevated audit costs. Nevis continues to expand geographically, with growth in New Jersey and Missouri, and anticipates increased sales from its new hemp-derived THC beverage. The company’s asset-light licensing model supports high margins and adaptability to regulatory changes, positioning it for growth as the cannabis beverage market matures.

Nevis Brands Expands Cannabis Beverage Offerings in Illinois and the Carolinas

Nevis Brands Inc has launched its Major™ 100mg cannabis beverage shots in Illinois, expanding its presence in regulated dispensary markets. The company also announced new distribution agreements for its Happy Apple™ hemp-derived THC beverages in North Carolina and South Carolina, aiming to grow its retail presence in bars and specialty outlets. These strategic expansions are expected to enhance Nevis’s market position and revenue streams in both regulated and traditional retail channels.